PicoSure Pro, the first and only FDA-cleared 755nm picosecond laser on the market, delivers energy in one trillionth of a second, utilizing pressure instead of heat to provide safe and effective treatments for unwanted pigmentation and skin revitalization for all skin types.
According to a news release, PicoSure Pro was designed with an advanced Platinum Focus lens array to increase collagen and elastin to help combat wrinkles, acne scars and pores. With the addition of a flat lens, Cynosure said, PicoSure Pro represents the first and only picosecond laser FDA-cleared for treating pigment in melasma and other hyperpigmentation issues like nevus of Ota and Hori’s nevus.
Cynosure also said the system features enhancements such as a sleek, modern design, an intuitive graphic user interface and a new 5mm handpiece that is ideal for treating discrete lesions, lighter Fitzpatrick skin types and smaller treatment areas.
“As inventors of picosecond aesthetic laser technology, we are constantly challenging ourselves to continually drive innovation forward. Whether we’re developing new devices or improving upon our trusted flagship products, we’re focused on addressing the unmet needs of our practitioners to ensure the best possible outcomes for their patients and practice,” said Todd Tillemans, Chief Executive Officer of Cynosure. “From a 50% increase in energy to new handpieces and an adjustable fluence, the performance enhancements made to the PicoSure Pro device provide practitioners with more versatility than ever before, allowing them to efficiently treat more patients per day and provide better outcomes in less time.”
Cynosure was previously part of Hologic, following a $1.65 billion acquisition in March 2017. Hologic went on to sell the Cynosure business for approximately $205 million to an affiliate of investment funds managed by Clayton, Dubilier & Rice in November 2019.